Vascular patent for HealthLinx
Wednesday, 17 September, 2008
HealthLinx [ASX: HTX] has been granted a US patent related to the company's vascular permeability program.
Licensed from the University of Virginia, the patent is related to the inhibition of the p21 activated kinase pathway as a treatment for disorders caused by aberrant vascular permeability.
It has widespread potential applications, including ischemia, stroke or burns.
The patent also forms part of the drug candidate CR014, a potential treatment for acute respiratory distress syndrome (ARDS) that the company is developing with the Canadian-based InSymbiosis.
No effective therapeutic treatments are available for the disease, which has a morbidity rate as high as 40 percent.
HealthLinx and InSymbiosis are preparing to embark on a preclinical development program for CR014.
Overuse of inhalers can increase heart attack risk
Overuse of reliever inhalers is associated with higher risks of developing and dying from...
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
